Success Metrics

Clinical Success Rate
86.7%

Based on 13 completed trials

Completion Rate
87%(13/15)
Active Trials
7(22%)
Results Posted
62%(8 trials)
Terminated
2(6%)

Phase Distribution

Ph early_phase_1
2
6%
Ph phase_1
10
31%
Ph not_applicable
6
19%
Ph phase_2
5
16%
Ph phase_4
4
13%

Phase Distribution

12

Early Stage

5

Mid Stage

4

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
2(7.4%)
Phase 1Safety & dosage
10(37.0%)
Phase 2Efficacy & side effects
5(18.5%)
Phase 4Post-market surveillance
4(14.8%)
N/ANon-phased studies
6(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

65.0%

13 of 20 finished

Non-Completion Rate

35.0%

7 ended early

Currently Active

7

trials recruiting

Total Trials

32

all time

Status Distribution
Active(7)
Completed(13)
Terminated(7)
Other(5)

Detailed Status

Completed13
Recruiting7
Withdrawn5
unknown5
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
32
Active
7
Success Rate
86.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (7.4%)
Phase 110 (37.0%)
Phase 25 (18.5%)
Phase 44 (14.8%)
N/A6 (22.2%)

Trials by Status

withdrawn516%
terminated26%
completed1341%
recruiting722%
unknown516%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT02531880Phase 1

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Recruiting
NCT05692635Phase 2

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Recruiting
NCT04727242Phase 2

CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

Completed
NCT03154996Phase 1

Chronic Convection Enhanced Delivery of Topotecan

Completed
NCT02390635Phase 1

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Recruiting
NCT03067467

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Recruiting
NCT03270059Phase 2

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Recruiting
NCT02648009Phase 1

Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection

Recruiting
NCT04474353Phase 1

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Completed
NCT05783271Not Applicable

Validity of Parametric MRI Using VIRADS

Recruiting
NCT04809584

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Unknown
NCT03565367Phase 1

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

Completed
NCT00659126Phase 2

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Terminated
NCT00978562Early Phase 1

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

Completed
NCT00103038Not Applicable

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

Completed
NCT02163005Phase 4

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

Withdrawn
NCT02598674

Severe Sepsis in Children - IMPRESS-C

Withdrawn
NCT02530931Phase 4

Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease

Terminated
NCT02783768Early Phase 1

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

Completed
NCT02599844

Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
32